Risk factor
Sufficiently resilient to price shocks
Profitability factor
Poor growth
About
Founded in 1990 and headquartered in Dalian, China, Jinhe Biotechnology Co. Ltd. focuses on the development and distribution of animal health pharmaceuticals both domestically and internationally. The company provides chlortetracycline in a feed-grade formulation, an antimicrobial compound vital for preventing and treating conditions like white dysentery, enteritis, pneumonia, typhoid, paratyphoid, and cholera in poultry and livestock. Additionally, its offerings include chlortetracycline hydrochloride, utilized to combat pullorum disease, typhoid, swine enteritis, and other bacterial ailments such as paratyphoid and cholera. Jinhe Biotechnology extends its market reach globally, exporting these veterinary solutions to regions including the United States, Southeast Asia, Latin America, and Europe.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair